187 related articles for article (PubMed ID: 37838774)
1. Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer.
Mondal T; Gaur H; Wamba BEN; Michalak AG; Stout C; Watson MR; Aleixo SL; Singh A; Condello S; Faller R; Leiserowitz GS; Bhatnagar S; Tushir-Singh J
Cell Death Differ; 2023 Nov; 30(11):2408-2431. PubMed ID: 37838774
[TBL] [Abstract][Full Text] [Related]
2. A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy.
Upadhyay R; Boiarsky JA; Pantsulaia G; Svensson-Arvelund J; Lin MJ; Wroblewska A; Bhalla S; Scholler N; Bot A; Rossi JM; Sadek N; Parekh S; Lagana A; Baccarini A; Merad M; Brown BD; Brody JD
Cancer Discov; 2021 Mar; 11(3):599-613. PubMed ID: 33334730
[TBL] [Abstract][Full Text] [Related]
3. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome.
Del-Rey M; Ruiz-Contreras J; Bosque A; Calleja S; Gomez-Rial J; Roldan E; Morales P; Serrano A; Anel A; Paz-Artal E; Allende LM
Blood; 2006 Aug; 108(4):1306-12. PubMed ID: 16627752
[TBL] [Abstract][Full Text] [Related]
4. CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30
Hong LK; Chen Y; Smith CC; Montgomery SA; Vincent BG; Dotti G; Savoldo B
Cancer Immunol Res; 2018 Oct; 6(10):1274-1287. PubMed ID: 30087115
[TBL] [Abstract][Full Text] [Related]
5. A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors.
Shivange G; Mondal T; Lyerly E; Bhatnagar S; Landen CN; Reddy S; Kim J; Doan B; Riddle P; Tushir-Singh J
Cell Rep; 2021 Nov; 37(5):109953. PubMed ID: 34731630
[TBL] [Abstract][Full Text] [Related]
6. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
7. Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy.
Anderson KG; Oda SK; Bates BM; Burnett MG; Rodgers Suarez M; Ruskin SL; Greenberg PD
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264436
[TBL] [Abstract][Full Text] [Related]
8. Super-Resolution Imaging of Fas/CD95 Reorganization Induced by Membrane-Bound Fas Ligand Reveals Nanoscale Clustering Upstream of FADD Recruitment.
Frazzette N; Cruz AC; Wu X; Hammer JA; Lippincott-Schwartz J; Siegel RM; Sengupta P
Cells; 2022 Jun; 11(12):. PubMed ID: 35741037
[TBL] [Abstract][Full Text] [Related]
9. Death of solid tumor cells induced by Fas ligand expressing primary myoblasts.
Hofmann A; Blau HM
Somat Cell Mol Genet; 1997 Jul; 23(4):249-57. PubMed ID: 9542527
[TBL] [Abstract][Full Text] [Related]
10. Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells.
Gopalan B; Litvak A; Sharma S; Mhashilkar AM; Chada S; Ramesh R
Cancer Res; 2005 Apr; 65(8):3017-24. PubMed ID: 15833826
[TBL] [Abstract][Full Text] [Related]
11. Revisiting autoimmune lymphoproliferative syndrome caused by Fas ligand mutations.
Maccari ME; Schneider P; Smulski CR; Meinhardt A; Pinto F; Gonzalez-Granado LI; Schuetz C; Sica MP; Gross M; Fuchs I; Kury P; Heeg M; Vocat T; Willen L; Thomas C; Hühn R; Magerus A; Lorenz M; Schwarz K; Rieux-Laucat F; Ehl S; Rensing-Ehl A
J Allergy Clin Immunol; 2023 May; 151(5):1391-1401.e7. PubMed ID: 36621650
[TBL] [Abstract][Full Text] [Related]
12. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts.
Gajate C; Mollinedo F
Blood; 2007 Jan; 109(2):711-9. PubMed ID: 17003375
[TBL] [Abstract][Full Text] [Related]
13. E2f2 Attenuates Apoptosis of Activated T Lymphocytes and Protects from Immune-Mediated Injury through Repression of Fas and FasL.
Mustafa N; Mitxelena J; Infante A; Zenarruzabeitia O; Eriz A; Iglesias-Ara A; Zubiaga AM
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008734
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes.
Badley AD; McElhinny JA; Leibson PJ; Lynch DH; Alderson MR; Paya CV
J Virol; 1996 Jan; 70(1):199-206. PubMed ID: 8523526
[TBL] [Abstract][Full Text] [Related]
15. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
Sneller MC; Wang J; Dale JK; Strober W; Middelton LA; Choi Y; Fleisher TA; Lim MS; Jaffe ES; Puck JM; Lenardo MJ; Straus SE
Blood; 1997 Feb; 89(4):1341-8. PubMed ID: 9028957
[TBL] [Abstract][Full Text] [Related]
16. The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions.
Rieux-Laucat F; Magérus-Chatinet A; Neven B
J Clin Immunol; 2018 Jul; 38(5):558-568. PubMed ID: 29911256
[TBL] [Abstract][Full Text] [Related]
17. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia.
Aspinall AI; Pinto A; Auer IA; Bridges P; Luider J; Dimnik L; Patel KD; Jorgenson K; Woodman RC
Blood Cells Mol Dis; 1999; 25(3-4):227-38. PubMed ID: 10575548
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune lymphoproliferative syndrome due to FAS mutations outside the signal-transducing death domain: molecular mechanisms and clinical penetrance.
Hsu AP; Dowdell KC; Davis J; Niemela JE; Anderson SM; Shaw PA; Rao VK; Puck JM
Genet Med; 2012 Jan; 14(1):81-9. PubMed ID: 22237435
[TBL] [Abstract][Full Text] [Related]
19. Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib.
Bi LL; Pan G; Atkinson TP; Zheng L; Dale JK; Makris C; Reddy V; McDonald JM; Siegel RM; Puck JM; Lenardo MJ; Straus SE
BMC Med Genet; 2007 Jul; 8():41. PubMed ID: 17605793
[TBL] [Abstract][Full Text] [Related]
20. Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy.
Gajate C; Mollinedo F
J Biol Chem; 2005 Mar; 280(12):11641-7. PubMed ID: 15659383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
